Quach, H., Perrot, A., Matous, J., Biran, N., Berdeja, J., Dorritie, K., Elssen, J., Touzeau, C., Anguille, S., Parmar, G., Spencer, A., Kint, N., Hulin, C., Boyd, K., Popat, R., Plattel, W., Suvannasankha, A., Rachamalla, A., Nguyen, A., Cortes-Selva, D., Campagna, M., Masterson, T., Vreys, V., Barreyro, P., Mason, G., Renaud, T., Searle, D. E. (2025). Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study. Blood. https://doi.org/10.1182/blood-2025-2282